Vaxcyte (PCVX) Corporate presentation summary

Mission and platform overview

• Focused on engineering high-fidelity vaccines to protect against bacterial diseases globally.

• Utilizes a proprietary cell-free protein synthesis platform (XpressCF) enabling rapid, flexible, and scalable vaccine development.

• Platform allows site-specific conjugation, producing carrier-sparing conjugates for broader-spectrum vaccines.

Pneumococcal conjugate vaccine (PCV) franchise

• VAX-31 is the broadest-spectrum PCV in clinical development, designed to cover ~95% of invasive pneumococcal disease (IPD) in U.S. adults ≥50 years.

• Enrollment completed in three Phase 3 adult trials (OPUS-1, OPUS-2, OPUS-3) and a Phase 2 infant study.

• VAX-24, a 24-valent PCV, showed positive Phase 2 results in infants, with robust immune responses and safety similar to PCV20.

• VAX-XL, a third-generation PCV, is in preclinical development to further expand coverage.

Clinical data and trial highlights

• VAX-31 Phase 1/2 adult data published in Lancet Infectious Diseases showed robust immune responses and safety comparable to PCV20.

• Phase 3 OPUS-1 trial compares VAX-31 to PCV21 and PCV20, targeting noninferiority for shared serotypes and superiority for unique serotypes.

• VAX-24 infant Phase 2 study met noninferiority criteria for most serotypes, with dose-dependent immunogenicity and minimal carrier suppression.

• Safety profiles for both VAX-31 and VAX-24 were similar to existing PCVs across all doses and cohorts.